Helicore Biopharma Emerges from Stealth to Continue Advancing Portfolio of First-in-Class GIP Antagonists for Obesity and Related Conditions
January 28, 2025 06:00 ET
|
Helicore Biopharma
Helicore Biopharma Emerges from Stealth to Continue Advancing Portfolio of First-in-Class GIP Antagonists for Obesity and Related Conditions
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Report Positive Topline Data from 8 mg Dose of Phase 2 Obesity Trial of GLP-1/GIP Receptor Dual Agonist HRS9531
January 13, 2025 08:00 ET
|
Kailera Therapeutics, Inc.
Kailera and Hengrui Pharma announced positive topline data from the 8 mg dose of Hengrui’s Phase 2 clinical trial of HRS9531, a GLP-1/GIP dual agonist.
RenaissThera Closes Seed Funding to Drive AI-Powered Therapies for Cardio-Metabolic Diseases
December 10, 2024 08:00 ET
|
RENAISSTHERA PRIVATE LIMITED
RenaissThera Closes Seed Funding to Drive AI-Powered Therapies for Cardio-Metabolic Diseases
RenaissThera Closes Seed Funding to Drive AI-Powered Therapies for Cardio-Metabolic Diseases
December 09, 2024 22:30 ET
|
RENAISSTHERA PRIVATE LIMITED
RenaissThera Closes Seed Funding to Drive AI-Powered Therapies for Cardio-Metabolic Diseases
Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions
October 01, 2024 07:00 ET
|
Kailera Therapeutics, Inc.
Kailera today announced its launch as a clinical-stage biopharmaceutical company advancing next-generation therapies for obesity and related conditions.
Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
August 10, 2023 16:05 ET
|
Structure Therapeutics Inc.
Completed enrollment in 12-week Phase 2a study of oral GLP-1 receptor agonist, GSBR-1290 Topline data from Phase 2a and Phase 1b multiple ascending dose study of GSBR-1290 expected in latter half of...
Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors
August 03, 2023 17:32 ET
|
Structure Therapeutics Inc.
SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for...
Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions
June 07, 2023 08:30 ET
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, China, June 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small...
Structure Therapeutics to Present at Jefferies Healthcare Conference
May 31, 2023 16:30 ET
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, May 31, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity
May 25, 2023 16:30 ET
|
Structure Therapeutics Inc.
12-week Phase 2a and Phase 1b multiple ascending dose (MAD) topline results expected to be announced in latter half of fourth quarter 2023 Ethnobridging study initiated in Japanese individuals and...